Library

ADB-5'Br-BUTINACA

ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, first detected in Philadelphia in the US in May 2022, and subsequently found in South Korea, Portugal and Sweden. It is specifically listed as an illegal drug in Italy, South Korea and several states in the US, and controlled under analogue legislation in various other jurisdictions.

Also known as: ADB-B-5Br-INACA, ADMB-B-5Br-INACA, ADB-5'Br-BINACA

Classification

  • Chemical: Cannabinoid
  • Chemical: Synthetic cannabinoid

Effects

  • Sedation
  • Anxiety
  • Paranoia
  • Euphoria
  • Dehydration

Routes of Administration

No route information available yet.

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu

ADB-5'Br-BUTINACA - Treoir substaint DrugsPRO

ADB-5'Br-BUTINACA: ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, first detected in Philadelphia in the US in May 2022, and subsequently found in South Korea, Portugal and Sweden. It is specificall

Related pages